---
title: Secondary hyperPTH
---
# Secondary hyperPTH

> ↑ PO4, ↑ FGF-23, ↓ calcitriol, & ↓ Ca → ↑ PTH → renal osteodystrophy

* Abnormalities of calcium, phosphorus, parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), and vitamin D metabolism

* Abnormalities in bone turnover, mineralization, volume linear growth, or strength

* Extraskeletal calcification


| Stage                              | 3     | 4      | 5       |
| ---                                | ---   | ---    | ---     |
| Target parathyroid hormone (pg/mL) | 35-70 | 70-110 | 150-600 |
* [[management of secondary hyperparathyroidism in adult nondialysis patients with chronic kidney disease]]
* [[chronic kidney disease (CKD)]]

* Phosphorus binders (take with meals!) (NEJM 2010;362:1312). Non-Ca–based binders (eg, sevelamer) a/w ↓ mort. compared to Ca-based (Lancet 2013;382:1268).
* 磷粘合劑（隨餐服用！）（NEJM 2010;362:1312）。
* 非鈣基粘合劑（例如司維拉姆）a/w ↓ mort.與基於鈣的 (Lancet 2013;382:1268) 相比。
可以考慮看看Lanthanum carbonate

* If PTH above goal then start vit. D (if 25-(OH)D <30) or 1,25-(OH)D analogue (calcitriol); stop if ↑ Ca (AJKD 2009;53:408)

* Cinacalcet (parathyroid Ca-sensing receptor agonist) if ↑ PTH despite phosphorus binders ± vit. D analogue (CJASN 2016;11:161); consider parathyroidectomy

see also
